[Recombinant plasma proteins for therapeutic use--status and developmental trends]

Area of Science:

• Biotechnology and Protein Engineering
• Transfusion Medicine
• Hematology

Context:

• Advancements in biotechnology and protein purification have enabled the development of recombinant human plasma proteins (rh pp).
• There is a critical need to mitigate the risks of transmitting viral infections (e.g., HIV, hepatitis) associated with plasma-derived products.
• The clinical application of rh pp is expanding, particularly in transfusion medicine and the treatment of blood disorders.

Purpose:

• To review the progress and potential of recombinant human plasma proteins (rh pp) as alternatives to conventional plasma-derived products.
• To highlight the development of rh pp for transfusion medicine and blood coagulation disorders.
• To assess the future role and comparative advantages of rh pp.

Summary:

• Numerous recombinant human plasma proteins (rh pp) have been developed due to progress in biotechnology and the need for safer alternatives to plasma-derived therapies.
• Key rh pp, including rh albumin, rh factor VIII (rh FVIII), rh FVIIa, and rh FIX, are either in clinical trials or under investigation for various medical applications.
• The genes and cDNA for relevant plasma proteins involved in blood coagulation have been cloned and characterized, facilitating rh pp production.

Impact:

• Recombinant human plasma proteins (rh pp) promise enhanced safety profiles by eliminating the risk of viral transmission inherent in plasma-derived products.
• The successful development and clinical integration of rh pp, such as rh FVIII and rh FVIIa, offer improved therapeutic options for patients with hemophilia and other coagulation disorders.
• Further evaluation of the advantages and disadvantages of rh pp compared to conventional plasma proteins will be crucial for their widespread adoption in the coming decade.